Your doctor prescribed Stelara because it’s the right treatment for you. And if your insurer denied it, the reason often has less to do with your medical needs than with a choice made to protect their bottom line.

Since brand Stelara’s patent expired, eight ustekinumab biosimilars have received FDA approval and several have launched commercially. The major PBMs are moving aggressively toward these biosimilars, though each is doing it differently and on its own timeline. Express Scripts excluded the IV formulation in January 2026 and is pulling subcutaneous Stelara for all users by July 2026. UnitedHealth’s Optum Rx and CVS Caremark are steering members toward their own affiliated biosimilars, even where brand Stelara technically remains on the list.

The biosimilars replacing it on formularies aren’t neutral choices. Each PBM tends to prefer its own affiliated product, meaning you may have no say in which specific version of ustekinumab you’re switched to.

If you’ve been stable on Stelara, this feels like a medical decision being made for you for business reasons that you have no stake in. If you’re a new patient, the step therapy and prior authorization requirements can still block access to ustekinumab entirely, biosimilar or not.

Fewer than 1% of denied claims are ever appealed, and insurers count on that. We see this first-hand at Claimable, where our appeals succeed over 80% of the time in established conditions.

Below, we break down each denial type and the specific strategies that win each one.

Why Insurance Companies Deny Stelara Coverage

The reason on your denial letter shapes your entire strategy, from the evidence you need to whether you file a formal appeal or a corrected resubmission.

Why Stelara Denials Are Their Own Category

Stelara (ustekinumab) is an IL-12/23 inhibitor approved for four conditions across two medical specialties: plaque psoriasis and psoriatic arthritis in dermatology, and Crohn’s disease and ulcerative colitis in gastroenterology. Step therapy requirements are completely different depending on your diagnosis, so two patients with identical denial language may need entirely different appeal strategies.

The biosimilar transition is the dominant factor in Stelara denials right now. With eight approved biosimilars and the major PBMs favoring their own affiliated versions (Cordavis for CVS Caremark, Nuvaila for Optum Rx, Quallent for Express Scripts/Cigna), many patients stable on brand Stelara are being pushed onto a biosimilar they didn’t choose. For many patients, that switch works fine. For some, it doesn’t, and those patients have the right to appeal.

For IBD patients, Stelara uses a weight-based IV induction dose (260 mg, 390 mg, or 520 mg depending on body weight) followed by subcutaneous maintenance every 8 to 12 weeks. This two-phase dosing structure creates a specific set of denial risks covered in the IV induction section below.

What We See In Stelara Appeals

Denial letters are written to end the conversation. Here are the most common types, what they mean, and where to start:

Formulary Removal and Biosimilar Switch

More patients are hitting this denial than any other. If you’ve been stable on brand Stelara and received a letter saying it’s no longer covered or no longer preferred, you’re in the middle of the fastest biosimilar formulary transition the industry has seen.

Ustekinumab biosimilars contain the same active ingredient, meet the same efficacy and safety standards, and are held to FDA bioequivalence requirements. A subset have also been designated interchangeable with Stelara — Wezlana was the first, followed by Selarsdi and others — which allows pharmacy-level substitution. Not all biosimilars carry that designation, but interchangeability speaks to substitution rules, not to whether a biosimilar is safe or effective; the non-interchangeable products meet the same clinical standards.

If you’re stable and have no history of problems with medication transitions, switching to your plan’s preferred biosimilar may be the fastest and simplest path to continued treatment. But if you don't want to switch, you shouldn't have to just because your insurance says so.

If you’ve experienced adverse reactions during prior biologic switches, if you have documented immunogenicity concerns, or if disease stability is fragile and your doctor believes any disruption carries clinical risk, your appeal case is particularly strong. Request a formulary exception, documenting your clinical stability on brand Stelara with objective measures and explain why switching introduces risk for your specific situation. If your state has non-medical switching protections, cite them directly.

Step Therapy Required

Step therapy means your insurer requires documented failure on cheaper therapies before they’ll approve ustekinumab (brand or biosimilar). Requirements often differ substantially by diagnosis:

The detail that changes outcomes: “failure” includes side effects, contraindications, and medical reasons a drug is inappropriate. Methotrexate is contraindicated in pregnancy and carries liver risk. Cyclosporine affects blood pressure and kidney function. If a required step therapy drug isn’t safe for you, document that directly.

The argument that wins: The 2025 ACG guidelines support ustekinumab as an advanced therapy for moderate-to-severe Crohn’s disease and UC without mandating TNF failure first. The AAD/NPF guidelines support IL-12/23 inhibitors for moderate-to-severe plaque psoriasis. The ACR/NPF 2018 guidelines include ustekinumab among the treatment options for active psoriatic arthritis. Citing these puts the insurer’s additional requirements in tension with professional consensus.

Not Medically Necessary

This denial is common. Sometimes it reflects a request that didn't spell out the clinical picture; other times a reviewer applied the plan's own criteria and decided your case didn't clearly meet them. Your appeal is where you make the full case either way.

A strong appeal includes diagnosis with ICD-10 codes, disease severity with objective measures (PASI or BSA for psoriasis, tender/swollen joint counts for PsA, CDAI or partial Mayo for IBD), complete treatment history with dates and reasons each therapy was stopped, and a clear clinical rationale for ustekinumab.

IV Induction Denied (IBD Patients)

For Crohn’s disease and ulcerative colitis, Stelara requires a single weight-based IV induction infusion before transitioning to subcutaneous maintenance. The induction dose is billed under the medical benefit, while the SC injections are billed under the pharmacy benefit. This dual-benefit split creates the same denial risk that Entyvio patients face.

Denials at the induction stage can occur because the PA was submitted under the wrong benefit, because the weight-based dosing wasn’t clearly documented, or because the insurer requires additional step therapy before approving the IV component.

Confirm that the PA is filed under the medical benefit with the correct HCPCS codes and that the weight-based dose matches your current body weight.

Dose or Interval Adjustment Denied

Maintenance dosing depends on your condition. For psoriasis and psoriatic arthritis, the standard interval is every 12 weeks. For Crohn’s disease and ulcerative colitis, the labeled maintenance dose is a subcutaneous injection every 8 weeks — but some IBD patients lose response at that interval and need it shortened further, to every 4 to 6 weeks, to maintain disease control. Insurers may deny the shortened interval as exceeding recommended dosing.

The argument that wins: dose optimization for ustekinumab is supported by clinical evidence and is standard gastroenterology practice. Your appeal should include objective evidence of inadequate response at the standard interval (worsening symptoms, rising inflammatory markers, low drug levels) and your prescriber’s rationale for the adjustment.

How to Appeal a Stelara Denial (Step by Step)

Step 1: Find Your Deadline

Most commercial plans allow 180 days. UnitedHealthcare limits many plans to 65 calendar days. Medicare plans follow CMS timelines. Don't miss the deadline, or you lose your right to appeal.

Step 2: Talk to Your Doctor

Both you and your doctor have the ability to appeal. Your doctor's appeal typically focuses on the clinical appeal (resubmitting the PA, writing a letter of medical necessity, requesting peer-to-peer review). You can file your own patient-initiated appeal, and can also include personal impact, policy precedent, and legal arguments. Patient appeals work on faster timelines and include more legal rights than a provider's appeal, so if your doctor can't or won't appeal, or if their appeal gets denied, a patient appeal is a great option.

Step 3: Verify Your Documentation

Confirm ICD-10 codes, disease severity measures appropriate to your condition, and treatment history with dates, doses, and reasons each therapy was stopped. For biosimilar switch appeals, document clinical stability on brand Stelara with objective metrics.

Step 4: Get a Letter of Medical Necessity

While appeals can be approved without a LOMN, it can be helpful – ask your doctor to write you one. A strong LOMN includes your diagnosis with severity scores, complete treatment history, and clinical rationale for vedolizumab addressing the insurer’s specific denial reason. Also include any denial-specific documentation, such as TNF contraindications for step therapy denials, clinical trajectory for continuation denials, or successful IV induction for transition denials.

Step 5: Build the Appeal Package

A complete appeal includes the cover letter, the LMN, supporting clinical records, and your personal statement. Structure it around: your story (the real-world impact of your condition), clinical evidence (ACG, AAD/NPF, or ACR/NPF guidelines supporting ustekinumab for your diagnosis), and policy and legal analysis (how your case meets the plan’s criteria, plus ACA protections and applicable state laws).

Step 6: Submit and Track

Submit per the denial letter instructions. Insurers must respond within 30 days (standard) or 72 hours (urgent). Keep records of everything.

Step 7: Escalate If Denied Again

You have the right to external review by an independent third party. Their decisions are binding in most states. Additional options include state Department of Insurance complaints, ERISA remedies, and state step therapy or non-medical switching laws.

Appeal Timelines: How Long Does a Stelara Appeal Take?

Complete submissions move faster. The average Claimable appeal gets a response in just 10 days.

FAQs

Why was my Stelara denied if my plan used to cover it?

Since brand Stelara’s patent expired, the major PBMs have been shifting their formularies toward lower-cost biosimilars. Your plan likely still covers ustekinumab, but may now require the biosimilar version. If you need to stay on brand Stelara for clinical reasons, that requires a formulary exception with supporting documentation.

Can I appeal a Stelara denial myself?

Yes. Patient appeals run on a separate legal track from your doctor’s clinical appeal, with guaranteed response timelines, the right to external review, and multiple levels of internal appeal.

What if my insurer wants me to switch to a Stelara biosimilar?

For most patients, the switch is clinically straightforward. Ustekinumab biosimilars meet the same FDA standards as brand Stelara, and several are designated interchangeable. If you have a documented clinical reason to stay on brand (adverse reaction history, immunogenicity concerns, fragile disease stability), request a formulary exception with supporting documentation from your prescriber. Some plans may approve brand Stelara but require you to pay the cost difference.

How many Stelara biosimilars are there?

Eight ustekinumab biosimilars have been FDA-approved as of mid-2026, and several have launched commercially. The specific biosimilar your plan prefers depends on your PBM. All are approved for the same indications as brand Stelara: plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.

How much does Stelara cost without insurance?

Brand Stelara’s list price is among the highest for any biologic. Biosimilars are priced significantly lower. Johnson & Johnson offers financial support through the Janssen CarePath program, and biosimilar manufacturers have their own copay and patient assistance programs. The IRA negotiated maximum fair price for Stelara in 2026 is 66% below the 2023 list price, which primarily affects Medicare Part D.

Claimable’s physician-led team has helped patients recover over $30 million in care access by fighting insurance denials. We’re SOC 2 Type II certified and HIPAA compliant. Learn more about how Claimable works →